Last reviewed · How we verify

Low Dose - SkQ1 — Competitive Intelligence Brief

Low Dose - SkQ1 (Low Dose - SkQ1) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mitochondria-targeted antioxidant. Area: Ophthalmology; Age-related degenerative diseases.

phase 3 Mitochondria-targeted antioxidant Mitochondrial reactive oxygen species (ROS) Ophthalmology; Age-related degenerative diseases Small molecule Live · refreshed every 30 min

Target snapshot

Low Dose - SkQ1 (Low Dose - SkQ1) — Mitotech, SA. SkQ1 is a mitochondria-targeted antioxidant that accumulates in mitochondria to neutralize reactive oxygen species and protect against oxidative damage.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Low Dose - SkQ1 TARGET Low Dose - SkQ1 Mitotech, SA phase 3 Mitochondria-targeted antioxidant Mitochondrial reactive oxygen species (ROS)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mitochondria-targeted antioxidant class)

  1. Mitotech, SA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Low Dose - SkQ1 — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-skq1. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing